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Key points: 
 
1. Sequential Probability Ratio Tests (SPRT) may have a role in detecting signals 
from spontaneous reports of suspected adverse drug reactions. They have 
somewhat different properties to other commonly used statistical methods for that 
purpose. 
 
2. Using a combination of variable hypothesised relative risks (hRRs) allows for the 
detection of different types of adverse events (AEs). For drug-AE pairs that are 
rare with low expected counts, we need to apply a higher hRR for the SPRT 
method to pick up signals of disproportionate reporting of concern. On the other 
hand, a lower hRR will be useful for the more common drug-AE pairs. 
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Detecting signals of disproportionate reporting from Singapore’s 
spontaneous adverse event reporting system – an application of 
the Sequential Probability Ratio Test  
 
Abstract 
 
Introduction: 
The ability to detect safety concerns from spontaneous adverse drug reaction reports 
in a timely and efficient manner remains important in public health.  
 
Objective: 
This paper explores the behaviour of the Sequential Probability Ratio Test (SPRT) 
and ability to detect signals of disproportionate reporting (SDRs) in the Singapore 
context. 
 
Methods:  
We used SPRT with a combination of two hypothesised relative risks (hRRs) of 2 
and 4.1 to detect signals of both common and rare adverse events in our small 
database. We compared SPRT with other methods in terms of number of signals 
detected and whether labelled adverse drug reactions were detected or the reaction 
terms were considered serious. The other methods used were reporting odds ratio 
(ROR), Bayesian Confidence Propagation Neural Network (BCPNN) and Gamma 
Poisson Shrinker (GPS). 
 
Results: 
The SPRT produced 2187 signals in common with all methods, 268 unique signals, 
70 signals in common with at least one other method, and did not produce signals in 
178 cases where two other methods detected them, and 403 signals unique to one 
of the other methods. In terms of sensitivity, ROR performed better than other 
methods, but the SPRT method found more new signals. The performances of the 
methods were similar for negative predictive value and specificity. 
 
Conclusions:  
Using a combination of hRRs for SPRT could be a useful screening tool for 
regulatory agencies, and more detailed investigation of the medical utility of the 
system is merited. 
 
 
(238 words) 
3 
 
Detecting signals of disproportionate reporting from Singapore’s 
spontaneous adverse event reporting system – an application of 
the Sequential Probability Ratio Test  
 
1. INTRODUCTION 
 
Post-marketing surveillance of drugs and vaccines is important to minimise risks with 
marketed drugs. In practice, spontaneous suspected adverse drug reaction (ADR) 
reporting remains the main source of information for regulators in this monitoring [1]. 
Pharmacovigilance distinguishes true ADRs from “adverse events” (AEs) that are not 
caused by the drug in question. A signal is a potential safety concern that a drug may 
be associated with a previously unrecognised hazard requiring further investigation 
[2]. 
 
Since 1993, the Vigilance and Compliance Branch of the Singapore Health Sciences 
Authority (HSA) receives spontaneous local ADR reports from healthcare 
professionals (e.g. 83.2% from clinicians, 12.2% from pharmacists, 2.7% from other 
healthcare professionals and 1.9% from pharmaceutical companies via facsimile, 
mail or online). Its Spontaneous Reports System (SRS) database has, in recent 
years, also received reports from the public healthcare institutions in real time via the 
Critical Medical Information Store (CMIS), and as a result, there has been a major 
increase of 40-fold in the number of ADR reports received regularly [3]. The numbers 
of reports received annually is now about 20,000. 
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Statistical “data mining” methods emerged in the late 1990s to complement the 
traditional manual review, and these are commonly called ‘disproportionality 
analysis’ [4, 5]. Some examples of frequentist statistical methods are the proportional 
reporting ratio (PRR), reporting odds ratio (ROR) [6-8]. Examples of Bayesian 
methods are the Bayesian Confidence Propagation Neural Network (BCPNN) [7, 9], 
Gamma Poisson Shrinker (GPS) [10] and Multi-item Gamma Poisson Shrinker 
(MGPS). The MGPS is now used by the US Food and Drug Administration (FDA) 
and the UK Medicines and Healthcare products Regulatory Agency (MHRA) [11, 12].  
All these methods are based around the ratio of observed-to-expected counts of 
reports to obtain signals, and many studies have shown that no single signal 
detection algorithm (SDA) provides uniformly better performance [13]. The 
commonly used methods do not allow for multiple looks at the accumulating data 
over time, which can result in large numbers of false positive findings [12]. 
 
One method, the Sequential Probability Ratio Test (SPRT), has less concern 
associated with multiple testing over time; it is specifically designed to make 
allowance for multiple looks at data over time.  
 
SPRT was developed by Wald in the 1940s [14, 15]  and has mainly been used in 
process monitoring. A review of the literature showed that the SPRT may offer 
advantages over the other methods to overcome multiple testing problems [16-18]. It 
has been used in the context of scanning electronic health records, but has not had 
extensive evaluation for spontaneous reports.  
 
Specifically, SPRT compares two hypotheses based on the likelihood of observing 
the data given those hypotheses [17, 19]. Unlike the other methods, SPRT is based 
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on the difference between (rather than the ratio of) the observed and expected 
values. However, there is limited research conducted on SPRT to evaluate its 
performance in an SRS database similar to Singapore’s, and a previous evaluation 
of SPRT used a single alternative hypothesis on simulated data [20]. On theoretical 
grounds, at least, the methods that do not allow for this form of multiple testing over 
time will have a higher rate of false positive findings – false signals. 
 
This paper explores how SPRT behaves and reviews its utility and applicability to 
pick up signals of disproportionate reporting (SDRs) for potential drug safety signals 
in the Singapore context. We also compare the performance of SPRT with three 
other SDA, namely ROR, BCPNN and GPS. 
 
2. METHODS 
 
The spontaneous reporting database in Singapore has been described by Ang et al 
[21]. In the database, each valid report has at least one product and at least one 
suspected ADR term included. Products are coded using standardised drug names, 
and adverse reaction terms are coded using the World Health Organisation Adverse 
Reaction Terminology (WHO-ART) (version 151) [22].  
 
The SPRT method requires that specific hypotheses regarding a relative risk to be 
detected are set out, and in the context of signals of ADRs, some arise from 
relatively frequently occurring AEs where small relative risks are nevertheless 
potentially important, while others are from rare events where only higher relative 
risks can be detected. The details of the SPRT method are described in the 
‘Appendix’, together with a brief description of the other methods used here, 
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including the criteria that determine whether the counts for particular drug-AE pairs 
constitute a signal. 
 
We analysed signals using all data from 1993 to 2013, and in additional analyses, 
also reviewed the data as they were up to 2011 and examined the new signals that 
arose in 2012 and 2013, mirroring what is done in practice with accumulating data.  
We also classified the drug-AE pairs in terms of seriousness of AE and whether the 
AE was labelled for that drug or not.  
 
We evaluated the methods, as most other comparisons have done, using sensitivity, 
specificity, negative predictive value (NPV), and positive predictive value (PPV), 
considering factors such as whether the pair is a significant SDR and whether the 
drug-AE pairs are labelled. The drug-AE pairs were reviewed by a senior pharmacist 
and considered as labelled if they were mentioned in the Micromedex®  [23] or 
current regulatory agency-approved drug labels in Singapore. It could be exact word-
to-word matching or synonymously labelled (same meaning). The AE terms were 
considered as serious if they exist in the WHO critical terms list or medically 
significant suspected serious ADRs by the US FDA or in the Important Medical Event 
Terms (IME) list developed by the EudraVigilance Expert Working Group [22, 24, 
25]. All the analyses were performed using R software, version 3.3.1 [26], including a 
signal detection package PhViD [27].   
 
3. RESULTS 
 
The HSA received a total of 151,180 AE reports from 1993 to 2013; these reports 
involved 23,183 unique drug-AE pairs. There were 1569 different suspected drug 
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substances and 1014 different AE terms. If every drug had reports for every possible 
AE, then all possible combinations of drug (1569 drugs) with AE term (1014 terms) 
would mean that there were potentially 1,590,966 possible pairs (1569 x 1014). Of 
those possible combinations, only 23,183 (1.5%) unique pairs actually occurred. The 
counts in each of these 23,183 cells had each of the methods applied to them. 
 
The effect of the two hypothesised relative risks (hRRs) used for detecting signals 
using SPRT with hRR=2 or hRR=4.1, is shown in Table 1 where we show the 
distribution of observed and expected counts where signals are detected, giving 
medians and 5th and 95th centiles. We analysed the SDRs in terms of seriousness 
of AE and whether the AE is labelled or not; for the period from 1993 to 2013, a total 
of 137 unique serious and non-labelled drug-AE pairs were signalled by SPRT. Of 
the 137 drug-AE pairs, 88 drug-AE pairs were not picked up by hRR=2 as the 
number of observed counts was less than five.  
 
The ROR and SPRT methods detected more SDR compared to BCPNN and GPS. 
Fig. 1 is the Venn diagram that shows the overlap of significant pairs detected by 
each method for the complete data from 1993 to 2013. The SDRs detected by the 
BCPNN method are a subset of the other methods. It is clear from this that the large 
majority (70%) of signals were detected by all methods (2187/3106). SPRT detected 
268 signals (N < 3) that were not detected by other methods, while ROR detected 
400 signals that were not detected by the other methods.  
 
Comparisons were done by reviewing the numbers of new signals based on drug-AE 
combinations that had some reports in the database prior to that year but were not 
signals previously, and totally new signals, where the combination had reports for the 
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first time in the relevant period. Table 2 gives the number of new significant SDRs for 
each method for different quarters from 2012 to 2013. In general, SPRT tends to 
generate a higher percentage of new significant pairs compared to the other 
methods. 
 
To evaluate which methods performed better than the others, we reviewed the 
significant SDRs in terms of seriousness of AE, whether the AE is labelled or not 
labelled, PPV, NPV, sensitivity and specificity. In this analysis, the SPRT method 
detected more not labelled drug-AE pairs. In terms of PPV, ROR, BCPNN and GPS 
performed better than SPRT. In terms of sensitivity, ROR performed better than 
other methods. The performances of the methods were similar for NPV and 
specificity (see Table 3). 
 
4. DISCUSSION 
 
We have shown that the SPRT method has some different properties to the other 
methods and that it can be ‘tuned’ to detect signals for rare events as well as more 
frequent ones. The fact that the hRR has to be pre-specified, while apparently a 
disadvantage, can be utilised to obtain signals in different circumstances. This 
method may be suitable for databases with smaller total numbers of reports and 
where a signal would be detected even with smaller numbers, compared with 
databases containing many millions of reports, such as those of the FDA and the 
EU. 
 
More work may need to be done to investigate its use in practice and whether it 
should be an additional or an alternative method for use in the context of smaller 
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databases. There is no general ‘gold standard’ to define which of the drug-AE pairs 
are really true ADRs and which are not. Methods like ROR and GPS that have been 
used in the past may have led to labelling, but it is not certain that all such 
associations are true ADRs. Individual regulatory authorities may need to examine 
the characteristics of the signals detected and not detected by the different methods 
in their own data. 
 
Singapore, although having a high reporting rate based on number of AE reports 
received per million inhabitants, is a small country and, therefore, its total number of 
reports is not that high. In this situation, there are drug-AE pairs of interest with small 
numbers of reports, and detecting SDRs using SPRT only with a small value of hRR 
will be problematic.  
 
For more rare events, it could be useful to adopt a higher hRR for early signalling 
purposes. For example, dabigatran (anticoagulant) and cerebral infarction was 
signalled earlier by hRR=4.1 when the number of observed counts was two. Using 
hRR=2 only gave a signal 9 months later when the number of observed counts 
reached five. ROR, BCPNN and GPS signalled it 3 months later than SPRT. 
Diltiazem (antihypertensive / anti-anginal) and vestibular disorders was signalled with 
hRR=4.1 in 2011 but not by hRR=2, ROR, BCPNN or GPS. Diltiazem and vestibular 
disorders is not included in the product label, but studies have shown migraine-
related dizziness or vertigo have been reported in 7% of patients [28]. Letrozole 
(anticancer) and epidermal necrolysis was signalled with hRR=4.1, ROR, BCPNN 
and GPS in 2011, but not by hRR=2. Letrozole and epidermal necrolysis is included 
in the product labels as either uncommon or rare. Vancomycin (antibiotic) and acute 
generalised exanthematous pustulosis was signalled using hRR=4.1, ROR and GPS 
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in 2011, and 6 months later by BCPNN. These findings suggest that SPRT could 
have a useful role, but it is not clearly superior to other methods. 
 
There are some signals probably resulting from confounding by indication, such as 
clozapine (antipsychotic) and neurosis, dapsone-pyrimethamine (combination of 
antibiotic and antimalarial) and infection, dasatinib (anticancer) and malignant 
neoplasm, hepatitis B immunoglobulin and viral hepatitis, pentamidine (antimicrobial) 
and pneumonia, and rivaroxaban (anticoagulant) and melaena. They may also be 
markers of the drug being ineffective, but deciding which is true is difficult, if not 
impossible, from spontaneous reports. 
 
While the SPRT method is intended to allow for multiple looks at accumulating data, 
it does not explicitly address other issues of multiplicity. There are over 20,000 drug-
AE pairs that are tested, and none of the methods make explicit allowance for this 
form of multiplicity. Here, reports are of suspected adverse drug reactions, so the 
possibility that they are all chance effects is not tenable, and the application of 
Bonferroni types of correction would be too extreme and lead to a notable loss of 
power. False discovery type methods, as described by Gould [12] and Ahmed et al. 
[29], do address these forms of multiplicity, and they could be applied to SPRT 
methods as well. 
 
Therefore, it is not possible to choose the hRR to be detected based solely on 
statistical grounds. Furthermore, it should be noted that the SPRT is a sequential 
test, and applying it to an existing database is not the most appropriate approach to 
its evaluation. The most appropriate approach would be to look at the newly arrived 
data and see what SDRs are detected. It is also clear that the actual hRR that is 
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most likely to be a real effect is of relevance. It is very likely that very high hRRs for 
reasonably common effects will have been detected in randomised trials used for 
licensing. However, extremely rare reactions would not be detected, and 
spontaneous AE reports are the best tool for detecting them.  
 
Having a large value of hRR will generate SDRs at very low observed or expected 
counts, but at high observed or expected counts, the signals might be missed. 
Hence, a detailed analysis of the effect of different hRR values on the database is 
necessary, and we have tried having different thresholds or hRR values for different 
observed counts or expected counts, but this does not seem practically sensible. 
However, having different thresholds for different types of AEs, depending on their 
rarity, may well be sensible. This may not be easy to define, but is worth exploring in 
the future. 
 
5. CONCLUSIONS 
 
It appears that SPRT may have some applications in the Singapore’s SRS. For AEs 
that are rare and thus expected to have low expected counts, applying a higher hRR 
for the SPRT method may pick up SDRs of concern. On the other hand, AEs that are 
more common need a lower hRR to weed out false positives. To appreciate the 
value of SPRT in the Singapore database, more in-depth analysis comparing the 
value of the signals picked up by varying the hRRs would be a useful next step of 
investigation.  Other countries, especially with smaller databases, may find this 
simple method of SPRT can be applied very easily to their databases and may 
provide signal detection for some rare events of significance to them. Assuming they 
have a database and the ability to produce the counts of the pairs, then it is easy to 
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apply the method, and this could be done using any spreadsheet or statistical 
software.  
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Appendix 
 
 
A1 Introduction 
The SPRT was developed by A. Wald in the 1940s [14,15] and was mainly used in 
process monitoring. A review of the pharmacovigilance literature showed that the 
SPRT may have useful properties not shared by other methods [16-18]. It has been 
used in the context of scanning electronic health records, particularly for vaccine 
studies, but has not had extensive evaluation for spontaneous reports. Specifically, 
SPRT compares two hypotheses based on the likelihood of observing the data given 
those hypotheses [19]. Unlike the other methods, SPRT is based on the difference 
between (rather than the ratio of) the observed and expected values. However, there 
is limited research conducted on SPRT to evaluate its performance in a 
Spontaneous Reports System (SRS) database similar to Singapore’s. A previous 
evaluation of SPRT used a single alternative hypothesis on simulated data [20]. On 
theoretical grounds, at least, the methods that do not allow for this form of multiple 
testing will have a higher rate of false positive findings – false signals. The method is 
essentially applied to a 2 x 2 table of data in the same way as other methods and 
where the emphasis is on obtaining an expected count assuming no association 
between the drug and the adverse event (AE). The method is applied to a single 
drug and adverse event and a determination of whether there is evidence of an 
association is made. The process is repeated, doing the same calculations for the 
next possible pairing and so on, for every drug-AE combination that occurs in the 
database. 
 
A1.1  The methods of use for SPRT in signal detection  
 
For any drug-AE pair, the analysis of quantitative data mining methods can be based 
on 2 x 2 contingency tables (Table 4). We focus on one particular drug-AE pair and 
include the totals of reports of other drugs and AEs.  
 
The number of reports listing drug and the AE are the observed values, and the 
expected value for each drug-AE pair is calculated (just as for a chi-square test), 
assuming independence, by the formula: 
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E =                                  A1.1 
 
We assume the continuously accumulating data in SRS is described by the Poisson 
distribution [17] which is widely used in pharmacoepidemiology and 
pharmacovigilance.  
 
The SPRT uses the log likelihood ratio (LLR) for the Poisson distribution calculated 
[6] by the formula: 
LLR = O × loge (hRR) − E × (hRR − 1)   A1.2 
 
Where for any drug-AE pair, 
 O is the observed number of reports, which is equal to cell a in Table 4. 
 hRR is the hypothesised relative risk of interest to constitute a signal. 
 E is the expected count as calculated at A1.1. 
 
This is a very simple calculation which uses the observed and expected counts 
multiplied by factors related to the hypothesised relative risk.  
 
A1.2. Varying thresholds in signal detection  
 
A and B are two thresholds in the SPRT method that determine, in this context, 
whether a signal has been detected:  
 
The signalling rules for SPRT are: 
 If LLR > B, then reject H0 and accept H1. 
 If LLR < A, then reject H1 and accept H0.  
In the conventional use of SPRT in process control one can stop monitoring if there 
is convincing evidence that there is no effect. However, in the case of post marketing 
surveillance, monitoring continues indefinitely, as signals can still occur subsequently 
due to various factors such as change in pattern of drug use and prescribing, so the 
threshold A is irrelevant in this context. 
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The threshold is calculated using α and β; α (type I error), the probability of incorrect 
rejection of a true null hypothesis, also called a "false positive". β (type II error) is the 
probability of accepting a false null hypothesis, also called a "false negative". 1 – β 
gives the power of the test. 
 
The values A and B are obtained using the formulae: 
A  loge {β / (1 – α)}    A1.3 
B  loge {(1 – β) / α}              A1.4 
  
To minimize the false positives, the value of α should be made small. To lessen the 
false negatives, the value of β should also be made small. We have used 
conventional α and β values at 0.05 and 0.20 respectively. This gives the 
approximate threshold value to be 2.77 for B. Different threshold values based on 
different choices of α and β can also be derived (see Table 5). 
 
A1.3. Observed and expected counts and their effect on LLR 
 
In order to understand how SPRT works, it is helpful to see what happens to the LLR 
when its parameters change. A graph of LLR is shown in Fig. 2 with varying values 
of hRR (in the range of 1 – 6) with a fixed observed count of 3 and an expected 
count of 1. This graph shows that the most likely value of hRR, (its maximum LLR) is 
at hRR of 3, and the likelihood of other values of hRR fall off the further hRR is from 
3. 
 
A1.4. Observed and expected counts and the relation to hRR 
 
In order to detect a signal, with a threshold value of 2.77 (i.e. α at 0.05 and β values 
at 0.20) and expected count of 1, using an alternative hypothesis hRR of 2 the 
minimum observed count is 6 (see Fig. 3). If the hRR is increased to 3, the LLR will 
cross the threshold when the observed count is greater than or equal to 5.  
 
If we reduce the expected value to zero (though we cannot ever have exactly zero in 
practice, but it can be very close to zero), then we see that the LLR formula in A1.2 
would approximately be equal to LLR = O × loge (hRR). Hence, we can make LLR 
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arbitrarily large with any observed count (and an extremely small expected count), 
including a low one, cross the threshold by having a sufficiently high value of the 
alternative hypothesis for hRR. Although this at first seems counter-intuitive, a very 
high hRR becomes more likely than the null even with a low observed count with an 
extremely small expected count. This is because the SPRT is a test comparing two 
simple hypotheses. Table A3 gives the hRR for the alternative hypothesis with a 
corresponding minimum observed count needed to cross a threshold of 2.77. It was 
observed that when SPRT was applied with a low hRR of 2 as the alternative 
hypothesis to our SRS database, it resulted in low numbers of SDRs. This could be 
explained as more than 90% of the drug-AE pairs in our SRS had less than 10 
reports (see Fig. 4). 
 
In all databases of spontaneous reports, low cell counts occur very frequently (and 
zero counts are the most frequent of all as noted above), and this is a particular 
issue with a relatively small database in Singapore compared to the US FDA 
Adverse Event Reporting System or the European EudraVigilance database.  On the 
other hand, if the alternative hypothesis for hRR is sufficiently high then signals can 
be obtained even with a single observed count. However, this means that with higher 
observed and expected values, but with lower values of hRR, then signals become 
more difficult to detect. 
 
A1.5. Use of two hypothesised values 
 
Initially SPRT with hRR = 2 was applied as has been used by others in references 
cited above. However, rare events with relatively small values of the observed and 
small values of the expected count, did not produce signals. Fig. 5 shows that the 
numbers of reports rise when the value of hRR reaches 4.1. This is because the 
minimum value for the observed count to be a signal with an expected close to zero, 
becomes 2 and so potentially many more cells have a count of 2 than a count of 3. 
Rarer AEs, such that although they only occur twice, but have a very small expected 
value and hence were not detected as a signal using SPRT with hRR=2 could be 
signalled more easily. Fig. 6 shows the overlap of significant pairs detected by SPRT 
with hRR=2 and hRR=4.1.  
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Signals with a notable excess based on a low number of reports with very low 
expected values are of medical interest as well as those with larger numbers of 
reports, so we decided to include all the SDRs generated by SPRT with hRR=2 or 
with hRR=4.1, if either crossed the threshold of 2.77. 
 
All these calculations are repeated using each drug-AE combination that exists. The 
calculations are quite simple; the complexity is in doing them for every combination 
and classifying each pair as giving rise to a signal or not. 
 
A1.6. Comparison of SPRT with other methods 
 
In our study, three methods in common use i.e. reporting odds ratio (ROR), Bayesian 
Confidence Propagation Neural Network (BCPNN) and Gamma Poisson Shrinker 
(GPS) were compared with SPRT. Virtually all those using these methods use a 
criterion based on a minimum count of drug–AE pairs (N ≥ 3) so this was also 
imposed here. The reason is that the analyses of ROR and GPS methods with small 
cell counts with one or two reports can result in statistical instability associated with 
disproportionalities. If the criterion of N ≥ 3 was not applied, ROR and GPS methods 
would generate many SDRs which are false positives. When we did not specify N ≥ 
3 for GPS, the method signalled several drug-AE pairs with two counts. As explained 
in the study by Ang et al [21], using a stricter threshold criterion for these methods 
will not give a better performance. Table 7 gives the formulae and thresholds for all 
the four methods compared in this study. Table 8 shows the formulae for calculating 
the sensitivity, specificity, positive predictive value and negative predictive value. 
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Tables and figures 
 
 
Table 1. Comparing SPRT with hRR=2 and hRR=4.1 in terms of seriousness of AE, whether the AE is labelled or not labelled, 
observed and expected values. 
 
Year SPRT 
No. of 
SDRs 
Not labelled    Labelled   Observed    Expected 
Serious 
Not 
serious  
Serious 
Not 
serious  
Median 
5th 
Percentile 
95th  
Percentile  
Median 
5th 
Percentile 
95th  
Percentile 
1993 – 2013 
hRR=2 & 
hRR=4.1 
(overlap) 
1232 47 71 
 
418 696 
 
11 5 141.8 
 
1 0.02 22.4 
hRR=2 only 200 2 6 
 
44 148 
 
32 10 716 
 
16.9 4 388.2 
hRR=4.1 only 1093 88 129   382 494   3 2 5   0.1 0.001 1 
 
hRR = risk of interest/relative risk in the alternative; SDR = signals of disproportionate reporting; SPRT = Sequential Probability Ratio Test; 5th Percentile is first 
5% of data values; 95th Percentile is first 95% of data values. 
 
 
s. It measures the veracity of SDR on labelledness.  
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Figure 1: Venn diagram for data from 1993 – 2013 to illustrate significant SDRs by 
the four methods and their inter-relationships (shapes not drawn to proportion).  
 
 
 
 
 
 
ROR = reporting odds ratio; BCPNN = Bayesian Confidence Propagation Neural Networks; GPS = 
Gamma Poisson Shrinkage; SPRT = Sequential Probability Ratio Test; SDR = signals of 
disproportionate reporting
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Table 2. Breakdown of no. of SDRs generated by each method according to different quarters of years 
 
    ROR 
 
BCPNN 
 
GPS 
 
SPRT (hRR=2 OR hRR=4.1) 
Cumulative 
(from 1993) 
No. of unique 
pairs  
Total no. 
of SDRs 
New 
Signals #  
Total no. 
of SDRs 
New 
Signals #  
Total no. 
of SDRs 
New 
Signals #  
Total no. 
of SDRs 
New Signals # 
2012-Q1 19,577 
 
2361 120 
 
1897 120 
 
1945 109 
 
2057 115 
2012-Q2 20,155 
 
2440 123 
 
1984 109 
 
2029 97 
 
2145 119 
2012-Q3 20,761 
 
2519 125 
 
2042 94 
 
2104 98 
 
2214 104 
2012-Q4 21,243 
 
2579 91 
 
2099 72 
 
2151 74 
 
2275 95 
2013-Q1 21,720 
 
2656 108 
 
2156 86 
 
2220 94 
 
2327 84 
2013-Q2 22,181 
 
2720 94 
 
2209 80 
 
2281 80 
 
2392 91 
2013-Q3 22,732 
 
2792 110 
 
2261 77 
 
2327 81 
 
2462 100 
2013-Q4 23,183 
 
2835 77 
 
2311 66 
 
2374 68 
 
2525 98 
 
# No. of new significant pairs which changed from not significant (No) to significant (Yes) and new significant pairs which were not present in the previous 
period. 
ROR = reporting odds ratio; BCPNN = Bayesian Confidence Propagation Neural Networks; GPS = Gamma Poisson Shrinkage; SPRT = Sequential Probability 
Ratio Test; SDR = signals of disproportionate reporting; 
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Table 3: Comparisons of methods in terms in terms of seriousness of AE, whether the AE is labelled or not labelled, PPV, NPV, 
sensitivity and specificity (1993 – 2013) 
 
 
 
   
Not Labelled Labelled       
Methods 
Total no. 
of SDRs 
generated 
Serious  
(%) 
Not serious 
(%) 
Serious 
(%) 
Not serious 
(%) 
PPV  
(%) 
NPV 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
Accuracy 
(%) 
ROR (LB>1 & N>=3) 2835 105 (3.7) 186 (6.7) 885 (31.2) 1659 (58.5) 89.7 32.8 15.7 95.8 39.7 
BCPNN 2311 86 (3.7) 146 (6.3) 758 (32.8) 1321 (57.2) 90.0 32.2 12.8 96.7 38.0 
GPS (EB05>1 & N>=3) 2374 88 (3.7) 150 (6.3) 774 (32.6) 1362 (57.3) 90.0 32.3 13.2 96.6 38.2 
SPRT (hRR=2 OR 
hRR=4.1) 
2525 137 (5.4) 206 (8.2) 844 (33.4) 1338 (53.0) 86.4 32.0 13.5 95.1 38.0 
 
ROR = reporting odds ratio; BCPNN = Bayesian Confidence Propagation Neural Networks; GPS = Gamma Poisson Shrinkage; SPRT = Sequential Probability 
Ratio Test; SDR = signals of disproportionate reporting; NPV = negative predictive value; PPV = positive predictive value 
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Table 4. 2 x 2 contingency tables of AE and drugs. 
 
 
No. of reports 
listing AE 
No .of reports 
not listing AE 
Total 
No. of reports 
listing drug 
a b a + b 
No. of reports 
not listing drug 
c d c + d 
Total a + c b + d a + b + c + d 
 
 
 
 
 
Table 5. Different threshold values based on different choices of α and β. 
 
α β Threshold A Threshold B 
0.01 0.01 -4.61 4.61 
0.05 0.05 -2.95 2.94 
0.05 0.1 -2.26 2.89 
0.05 0.2 -1.56 2.77 
0.1 0.1 -2.20 2.20 
0.1 0.2 -1.51 2.08 
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Figure 2: Graph of LLR with varying values of hRR for fixed O=3 and E=1. 
 
 
 
LLR: log likelihood ratio; O: observed number of reports; E: expected values for each drug-AE pair 
 
 
 
Figure 3:  LLR vs observed values for fixed hRR=2 and E=1 
LLR: log likelihood ratio; O: observed number of reports; hRR: hypothesised relative risk (risk of 
interest/relative risk in the alternative); E: expected values for each drug-AE pair. Threshold=2.77 
27 
 
 
  
Table 6. Varying values of hRR with corresponding qualifying SDRs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Distribution of number of reports received for drug-AE pairs (1993 – 2013) 
 
 
 
 
 
 
 
 
Cut-off of 
threshold (LLR) 
Expected 
value  
hRR Minimum 
observed value  
2.77 1 
 
2 6 and above 
3 5 and above 
4 5 and above 
8 5 and above 
    
2.77 ~0 2 4 and above 
3 3 and above 
4 2 and above 
8 2 and above 
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Figure 5: Total number of SDRs with increasing hRR for data from 1993 to 2013 
 
 
 
hRR = hypothesised relative risk (risk of interest/relative risk in the alternative); SDR = signals of 
disproportionate reporting; SPRT = Sequential Probability Ratio Test 
 
 
 
Figure 6: Venn diagrams showing overlap of SDRs detected by SPRT with hRR=2 
and hRR =4.1 (1993 – 2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hRR = hypothesised relative risk (risk of interest/relative risk in the alternative); SDR = 
signals of disproportionate reporting; SPRT = Sequential Probability Ratio Test 
 
1093 
1232 
200 
hRR = 2 
hRR = 4.1 
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Table 7. Formulas and thresholds of methods used 
 
Methods Formula  Threshold  
SPRT LLR = O × loge (hRR) – E × (hRR − 1) 2.77# 
ROR ROR = (a × d)/(b × c) ROR – 1.96SE > 1, N ≥ 3 
BCPNN IC = log2(O/E) IC – 1.96SD > 0 
GPS EBGM = e(EBln) EB05** > 1, N ≥ 3 
 
# α=0.05 and β=0.20,  SPRT = Sequential Probability Ratio Test; ROR = reporting odds ratio; BCPNN 
= Bayesian Confidence Propagation Neural Networks [30]; GPS = Gamma Poisson Shrinkage [2];  ** 
EB05 denotes fifth percentile of confidence limits of empirical Bayes geometric mean (EBGM). 
Calculations were done using R software and a signal detection package – PhVID was also used 
[26,27].  
 
 
 
Table 8. Concepts of sensitivity, specificity, positive predictive value, and negative 
predictive value. 
 
 
Gold standard (true causality) 
 
 
Result/signal Labelled  Not labelled  Total  
Yes TP FP TP +FP 
PPV =  
TP/(TP + FP) 
 
(true positive) (false positive) 
  
No FN TN 
 
FN + TN 
NPV =  
TN/(FN + TN) 
 
(false negative) (true negative) 
  
Total  TP+FN  FP + TN N=TP+FP+FN+TN 
Accuracy = 
(TP+TN)/N 
 
Sensitivity Specificity 
  
 
=  TP/(TP + FN ) 
=  
TN/(FP+TN) 
  
 
Sensitivity is the proportion of true positive signals based on those drug–AE pairs which were labeled. 
 
Specificity is the proportion of true negative signals that did not map to labeled drug–AE pairs. A high 
specificity indicates low false positive signals. 
 
Positive predictive value (PPV) is the proportion of the drug–AE pairs that were labeled and were 
signaled as statistically significant drug–AE pairs. 
 
Negative predictive value (NPV) is the proportion of the drug–AE pairs that were not labeled and were 
not signaled drug–AE pairs. 
 
Accuracy is the proportion of true signals (both positive and negative) based on total drug-AE pairs. It 
measures the veracity of SDR on labelledness.  
 
